FIELD OF APPLICATION DETAILS
Generic Name
Corifollitropin alfa
Active Ingredient
Corifollitropin alfa
Brand Names
Elonva
Drug Category
Gynecology
Drug Class
Palliative treatment, Immunosuppressive therapy
Dosage Forms
Injection, Injection, solution, Solution
Route of Administration
Subcutaneous, Parenteral
FDA Approval Status
Not approved

Corifollitropin Alfa: Overview

Corifollitropin alfa belongs to the class of peptide hormones and recombinant proteins. Produced via recombinant DNA technology, it is a highly specialized follicle-stimulating hormone (FSH) analogue. It was designed to possess a significantly extended half-life compared to traditional daily FSH therapies, easing the physical and psychological burden on women undergoing fertility treatments.

Corifollitropin Alfa: What Is It & How Does It Work?

Corifollitropin alfa acts as a sustained follicle stimulant by binding directly to the same receptors as naturally occurring human FSH, but with a structurally prolonged duration of action:

  • FSH Receptor Agonism: The drug binds to and activates the follicle-stimulating hormone receptor (FSHR) on the granulosa cells of the ovaries. This stimulation drives the recruitment, growth, and maturation of multiple ovarian follicles simultaneously.
  • Prolonged Pharmacokinetics: The extended action is achieved through a unique molecular structure. Using gene transfer techniques, the standard alpha-subunit of human FSH is noncovalently bound to a modified beta-subunit. This beta-subunit is elongated by fusing it with the carboxy-terminal peptide of the human chorionic gonadotrophin (hCG) beta-subunit.

Corifollitropin Alfa: FDA Approval & Uses

Understanding the regulatory status of corifollitropin alfa clarifies its international scope in controlled ovarian stimulation.

Global Regulatory Status

No. Corifollitropin alfa is Not Approved by the US Food and Drug Administration (FDA) for commercial distribution in the United States (the FDA issued a Complete Response Letter rejecting its application in 2014). However, it is fully approved and heavily marketed under the brand name Elonva in more than 75 countries, including throughout Europe and Asia.

Before Taking Corifollitropin Alfa: Contraindications & Precautions

Before starting treatment with or receiving corifollitropin alfa, patients must review key safety precautions and underlying health risks with their healthcare provider.

Who Should Not Take Corifollitropin Alfa?

  • Women with primary ovarian failure (where the ovaries no longer produce eggs).
  • Patients with uncontrolled thyroid or adrenal gland dysfunction, or tumors of the ovary, breast, uterus, pituitary, or hypothalamus.
  • Women with a history of Ovarian Hyperstimulation Syndrome (OHSS) or those with polycystic ovary syndrome (PCOS) who have a known extremely high baseline ovarian reserve, due to a severe risk of hyperstimulation.
  • Individuals with unexplained vaginal bleeding or ovarian cysts not related to PCOS.

Corifollitropin Alfa: Pregnancy & Breastfeeding

Because this medication is used strictly to induce follicular development prior to pregnancy, it is completely contraindicated during an existing pregnancy. There is no clinical indication for its use in pregnant or breastfeeding women.

Tell Your Doctor Before Taking Corifollitropin Alfa

Inform your fertility specialist if you have a history of blood clots, severe pelvic pain, or if you have previously had a severe hyper-response to fertility medications during a past IVF cycle.

Corifollitropin Alfa: Dosage & Administration

Because corifollitropin alfa is a long-acting recombinant formulation, dosing relies on a single injection to cover the initial stimulation week.

Standard Corifollitropin Alfa Dosing

  • Single-Dose Regimen: A single subcutaneous injection is administered on cycle day 2 or 3 of menstruation. This one injection covers the first 7 days of ovarian stimulation. If further stimulation is required after day 7, daily injections of standard recombinant FSH may be initiated until the follicles are ready for retrieval.

How Corifollitropin Alfa Is Administered

  • Dosage Forms: Supplied internationally as a pre-filled syringe containing an Injection Solution (typically 100 micrograms or 150 micrograms, dosed based on the patient’s body weight and age).
  • Administration Routes: Administered strictly via the Subcutaneous (Parenteral) route, usually injected into the abdominal wall.

Corifollitropin Alfa: Clinical Efficacy & Research

Clinical trials and extensive international fertility studies establish the sustained follicular stimulation efficacy of corifollitropin alfa. Research highlights its capacity to match the ongoing pregnancy and live birth outcomes of traditional daily recombinant FSH while eliminating daily injection burdens during the first week.

Trial Findings and Efficacy

Extensive global clinical trials and meta-analyses demonstrate that a single injection of corifollitropin alfa is just as efficacious as seven daily injections of traditional recombinant FSH in terms of clinical pregnancy rates, ongoing pregnancy rates, and live birth rates. By eliminating the need for daily injections during the first week of stimulation, it significantly reduces patient stress, injection site pain, and medication errors, drastically improving compliance in ART programs.

Corifollitropin Alfa: Side Effects & Safety Profile

BLACK BOX WARNING

Because corifollitropin alfa is an unapproved drug in the United States, it does not carry an FDA Black Box Warning. However, international regulatory guidelines highlight a severe, potentially life-threatening risk of Ovarian Hyperstimulation Syndrome (OHSS). Because the medication stays in the system for over a week, women who are “high responders” (producing too many eggs too quickly) cannot simply lower their dose mid-week, necessitating strict prophylactic management.

Understanding the side effect profile of corifollitropin alfa helps clinical teams and patients monitor for adverse reactions. While highly convenient, the long-acting nature of the drug means that its effects cannot be quickly stopped once injected, making careful patient selection critical.

Common Corifollitropin Alfa Side Effects

  • Pelvic discomfort, mild ovarian pain, and abdominal bloating.
  • Headaches and extreme fatigue.
  • Nausea and breast tenderness.
  • Injection site reactions (redness, bruising, or pain).

Serious Corifollitropin Alfa Adverse Events

  • Thromboembolic Events: A heightened risk of blood clots (deep vein thrombosis or pulmonary embolism) associated with rapid rises in estrogen and OHSS.
  • Ovarian Torsion: The physical twisting of an enlarged ovary, cutting off its blood supply and requiring emergency surgery.

Managing Corifollitropin Alfa Side Effects

Fertility specialists mandate frequent ultrasound and blood test monitoring during the stimulation week. If signs of severe OHSS develop, the cycle may be canceled, the egg retrieval delayed, or all resulting embryos frozen for a future transfer to prevent the hormones of pregnancy from worsening the OHSS.

Corifollitropin Alfa: Drug Interactions & What to Avoid

Corifollitropin alfa exhibits minimal cytochrome P450 interactions due to its peptide structure, though co-administration with other gonadotropins requires strict timing.

Key Corifollitropin Alfa Interactions

  • Other FSH Products: It is strictly contraindicated to administer additional recombinant FSH products during the first 7 days following the corifollitropin alfa injection, as this will lead to a massive overdose and highly likely trigger severe OHSS.

Corifollitropin Alfa: Food & Alcohol

There are no known food interactions. However, women undergoing IVF are generally advised to maintain a healthy diet, stay highly hydrated (especially to help mitigate mild OHSS symptoms), and avoid alcohol and recreational drugs to optimize egg quality and treatment success.

Corifollitropin Alfa: Missed Dose, Overdose & Storage

Proper handling, refrigeration, and precise cycle timing govern long-acting FSH management.

Missed Dose of Corifollitropin Alfa

The medication is given as a single, carefully timed injection managed by a fertility clinic. If the scheduled day for the injection is missed, the patient must contact their clinic immediately, as the timing of the menstrual cycle and the accompanying GnRH antagonist is highly time-sensitive.

Corifollitropin Alfa: Overdose

Administering a dose higher than recommended, or taking additional FSH within the 7-day window, constitutes an overdose. This drastically escalates the risk of severe Ovarian Hyperstimulation Syndrome. Management requires close hospital monitoring, fluid management, and potential drainage of abdominal fluid if severe OHSS occurs.

How to Store Corifollitropin Alfa

Store the pre-filled syringes in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze. It may be kept out of the refrigerator at room temperature (up to 25°C/77°F) for a maximum of one month, after which it must be used or discarded.

Corifollitropin Alfa: Patient Management & Guidelines

Effective clinical management relies on pre-treatment ovarian reserve screening, frequent transvaginal ultrasounds, and serum estradiol tracking.

Tests Before & During Corifollitropin Alfa Treatment

  • Ovarian Reserve Testing: Baseline AMH (Anti-Müllerian Hormone) and antral follicle count (AFC) ultrasounds are strictly required to ensure the patient is not at an unacceptably high risk for OHSS.
  • Transvaginal Ultrasounds: Frequent monitoring every few days to measure the size and number of developing follicles.
  • Serum Estradiol Levels: Blood tests to monitor the ovaries’ response and evaluate the risk of hyperstimulation.

Corifollitropin Alfa: Do’s and Don’ts

  • Do drink plenty of fluids and electrolyte-rich beverages if you feel bloated during the stimulation cycle.
  • Do immediately report severe abdominal pain, rapid weight gain, or shortness of breath to your clinic, as these are signs of OHSS.
  • Do not engage in vigorous exercise, heavy lifting, or high-impact activities during treatment, as your enlarged ovaries are at risk of twisting (ovarian torsion).

Frequently Asked Questions

What is Corifollitropin alfa used for?

It is a fertility medication used during in vitro fertilization (IVF) to stimulate a woman’s ovaries to produce multiple mature eggs at the same time.

How is it different from daily IVF injections?

Traditional IVF requires a woman to inject a follicle-stimulating hormone (FSH) into her stomach every single day. Corifollitropin alfa is specially engineered to last much longer in the body, meaning one single injection takes the place of seven daily injections.

Is Corifollitropin alfa approved in the United States?

No. The FDA did not approve this medication for use in the US. However, it is fully approved and widely used in over 75 other countries under the brand name Elonva.

What is OHSS and why is it a risk?

Ovarian Hyperstimulation Syndrome (OHSS) is a complication where the ovaries overreact to fertility drugs, becoming swollen and painful while fluid leaks into the abdomen and chest. Because corifollitropin alfa stays active in the body for a full week, the dose cannot be lowered mid-cycle if the ovaries start overreacting.

Who is not a good candidate for this medication?

Women with Polycystic Ovary Syndrome (PCOS) or a very high number of resting eggs are generally not good candidates, as their ovaries are highly sensitive and prone to dangerous hyperstimulation from long-acting drugs.

How is it administered?

It is given as a single subcutaneous injection (a tiny needle under the skin, usually in the lower abdomen) on the second or third day of the menstrual cycle.

Do I need more injections after the first week?

Usually, yes. The corifollitropin alfa injection covers the first 7 days. If your eggs need a few more days to fully mature, you will start taking daily traditional FSH injections from day 8 until it is time for the egg retrieval.

References

  • DrugBank Database – Corifollitropin Alfa Clinical and Pharmacological Profile
  • European Medicines Agency (EMA) Prescribing Information for Elonva
  • Clinical Guidelines for Controlled Ovarian Stimulation in Assisted Reproductive Technology

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding medical conditions or treatment plans.